A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Carbon dioxide (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Soleno Therapeutics
  • Most Recent Events

    • 09 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 09 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Actual initiation date (Jan 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top